Prévisions
L'objectif de cours moyen des analystes est de 8,20 € (+187,72 %). La médiane est de 8,20 € (+187,72 %).
| Acheter |
4 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Entera Bio gets shortened FDA approval pathway for oral osteoporosis drug EB613
The FDA has agreed to a shortened approval study design for EB613: a 12-month, double-blind, placebo-controlled Phase III trial instead of the originally planned 24 months. Entera Bio raised $275 million and plans to begin recruitment in 2026. EB613 is an oral teriparatide tablet targeting patients who refuse injectable therapies; in Phase II it showed total-hip BMD increases of 1.34–1.57% after six months. Despite the milestone, the stock fell sharply on the conference day as investors remain cautious pending additional efficacy and safety data. » Plus sur de.investing.com
Entera Bio posts wider Q2 loss as it ramps R&D ahead of EB613 Phase 3
Entera Bio reported a Q2 net loss of $7.3 million, or $0.14 per share, versus analyst expectations of a $0.09 per-share loss, driven by a $2.7 million non-cash warrant remeasurement and higher R&D spending. R&D rose to $3.2 million as the company prepares registrational work for its oral osteoporosis candidate EB613 after reaching FDA alignment on a 12-month Phase 3 design. Entera plans to start the pivotal trial in late 2026 with topline results targeted in H2 2028 and completed a $275 million private placement expected to extend its cash runway into 2030 (cash was $11.3 million at June 30). » Plus sur finance.yahoo.com
Entera Bio secures $10 million in private placement led by BVF Partners
Entera Bio completed a private placement of approximately $10 million, issuing 7,827,789 units at $1.2775 each; each unit includes a common share or a pre-funded warrant and a five-year warrant to purchase 1.5 shares at $1.24. Gross proceeds are about $10 million; if the warrants are fully exercised, an additional roughly $14.5 million could be raised, bringing total potential proceeds to about $24.5 million. Entera intends to use the funds to start the pivotal Phase 3 trial of EB613 in postmenopausal women with osteoporosis and for working capital; the company notes a strong liquidity position (current ratio 6.94). The stock rose 26% last week and is currently trading at $1.22, though InvestingPro considers the shares overvalued at this level. » Plus sur de.investing.com
Entera Bio secures $10 million private placement led by BVF Partners
Entera Bio completed a private placement of approximately 7,827,789 units at $1.2775 each, led by funds affiliated with BVF Partners, expected to generate gross proceeds of about $10 million. Each unit consists of a common share or a prepaid warrant plus a five-year warrant to purchase 1.5 common shares at $1.24; if fully exercised, additional proceeds of roughly $14.5 million could be raised (potential total proceeds ~ $24.5 million). The proceeds are intended to fund the phase 3 study of EB613 for the treatment of postmenopausal osteoporosis and for general corporate purposes; the securities are being offered pursuant to Section 4(a)(2). » Plus sur de.investing.com
Entera Bio to file phase‑3 protocol for EB613 in Q1 2026
Entera Bio will submit the final phase‑3 protocol for EB613, an oral PTH tablet for osteoporosis, to the FDA in Q1 2026. The filing follows the FDA’s December 2025 recognition of bone mineral density (BMD) as an approval‑relevant endpoint. The company expects results from an ongoing phase‑1 bridging study of the next‑gen formulation by the end of Q1 2026 and plans to accelerate development of EB612 for hypoparathyroidism in 2026. According to analysis, Entera shows a high current ratio of 10.83 and is in talks about strategic partnerships, but remains a loss‑making and volatile biotech stock. » Plus sur de.investing.com
Données financières
Au dernier trimestre, ENTERA BIO IS-,0000769 a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -13,77 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | 100,00 % |
| Bénéfice net | -13,77 M | 404,98 % |
| EBITDA | -6,41 M | 135,51 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 517,36 M € |
Nombre d'actions | 174,14 M |
Plus haut/bas sur 52 semaines | 3,83 € - 0,83 € |
| Dividendes | Non |
Bêta | 1,46 |
Ratio P/E | -8,39 |
Ratio PEG | 0,19 |
Ratio P/B | 1,72 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Entera Bio Ltd., une société biopharmaceutique au stade clinique, se concentre sur le développement et la commercialisation de médicaments à grosses molécules administrés par voie orale, destinés à répondre à des besoins médicaux non satisfaits. Parmi les principaux candidats-médicaments de la société, l'EB612, actuellement en essais cliniques de phase II pour le traitement de l'hypoparathyroïdie, et l'EB613, qui a achevé les essais cliniques de phase II pour le traitement de l'ostéoporose et se trouve également en essais cliniques de phase I pour le traitement des fractures non consolidées. La société dispose d'un accord de collaboration de recherche et de licence avec Amgen Inc. pour le développement et la découverte de candidats cliniques dans le domaine des maladies inflammatoires et d'autres maladies graves. Entera Bio Ltd. a été constituée en 2009 et a son siège à Jérusalem, en Israël.
| Nom | ENTERA BIO IS-,0000769 |
| PDG | Miranda J. Toledano |
| Siège social | Jerusalem,
jm Israël |
| Site web | |
| Secteur | Consommation de base |
| Industrie | Produits alimentaires |
| Introduction en bourse | 28/06/2018 |
| Employés | 27 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ENTX |
Frankfurt | 5DT.F |
Düsseldorf | 5DT.DU |